Bridgeway Capital Management’s Lexeo Therapeutics LXEO Stock Holding History
Bought
Maintained
Sold
Other funds holding LXEO
Bridgeway Capital Management's LXEO Position: Q3 2026 in Review
Bridgeway Capital Management opened a new position in Lexeo Therapeutics (LXEO) in Q3 2026: 58,993 shares worth $199K. The stake represents ﹤0.01% of the portfolio and ranks #1021 among its holdings. This is a return to the name: Bridgeway Capital Management previously reported a position in LXEO as recently as Q1 2026.
Bridgeway Capital Management first reported a position in LXEO in Q4 2024 and has held it in 7 quarters since. The position peaked at $428K in Q4 2024. 153 funds tracked by Wall St. Rank hold LXEO as of Q3 2026.
- Bridgeway Capital Management held 58,993 shares of Lexeo Therapeutics worth $199K as of Q3 2026.
- Lexeo Therapeutics was a new Bridgeway Capital Management position in Q3 2026.
- Lexeo Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1021 holding.
- Bridgeway Capital Management first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 7 quarters since.
- Bridgeway Capital Management's Lexeo Therapeutics position peaked at $428K in Q4 2024.
- 153 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q3 2026.
Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.